Replies to post #254177 on Biotech Values

[DewDiligence]

…my sense…is that SLRN will be spending a good chunk of that cash on further development in TED and that there is no reason for them to do so.

That may well happen but it’s not a given, IMO. After reporting middling clinical data that’s uncompetitive for the indication in question, biotech companies may need some time for the reality of the situation to sink in.